Paul Janssen Futurelab IP course starts April 19th
The J&J/Janssen Covid-19 vaccine that was recently approved by the FDA and EMA is produced using cell line PER.C6 that was originally developed and patented for a quite different application (i.e. gene therapy). Solid science and out-of-the-box creativity led to new applications and patents for PER.C6.
Interested to learn how the applications and intellectual property rights were extended? Join the Paul Janssen Futurelab new learning-by-doing online IP course that starts April 19th. For more info and a free demo see